Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA‐1273: A Danish Population‐Based Cohort Study
Otolaryngology–Head and Neck Surgery · 2023
DOI: 10.1002/ohn.394 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2023. Verfasst von Per Damkier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: COVID-19, Hearing Loss, Sensorineural, Vestibular Neuronitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To compare the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA‐1273 (Spikevax®; Moderna) to the occurrence among unvaccinated individuals. Study Design Cohort study.
Setting
Nationwide Danish health care registers comprised all Danish residents living in Denmark on October 1, 2020, who were 18 years or older or turned 18 in 2021.
Methods
We compared the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA‐1273 (Spikevax®; Moderna) (first, second, or third dose) against unvaccinated person time. Secondary outcomes were a first‐ever hospital diagnosis of vestibular neuritis and a hearing examination, by an ear‐nose‐throat (ENT) specialist, followed by a prescription of moderate to high‐dose prednisolone.
Results
BNT162b2 or mRNA‐1273 vaccine was not associated with an increased risk of receiving a discharge diagnosis of sudden sensorineural hearing loss (adjusted hazard ratio [HR]: 0.99, confidence interval [CI]: 0.59‐1.64) or vestibular neuritis (adjusted HR: 0.94, CI: 0.69‐1.24). We found a slightly increased risk (adjusted HR: 1.40, CI, 1.08‐1.81) of initiating moderate to high‐dose oral prednisolone following a visit to an ENT specialist within 21 days from receiving a messenger RNA (mRNA)‐based Covid‐19 vaccine.
Conclusion
Our findings do not suggest an increased risk of sudden sensorineural hearing loss or vestibular neuritis following mRNA‐based COVID‐19 vaccination. mRNA‐Covid‐19 vaccination may be associated with a small excess risk of a visit to an ENT specialist visit followed by a prescription of moderate to high doses of prednisolone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Pharmacy Department, Rotunda Hospital, Dublin, Ireland.
- School of Pharmacy and Biomolecular Science, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Research Unit for ORL-Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Per Damkier, Brian Cleary, Jesper Hallas, Jesper H Schmidt, Louise Ladebo, Peter B Jensen, Lars Christian Lund
Zitieren
APA
Damkier, P., Cleary, B., Hallas, J., Schmidt, J. H., Ladebo, L., Jensen, P. B., & Lund, L. C. (2023). Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA‐1273: A Danish Population‐Based Cohort Study. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.394
Vancouver
Damkier P, Cleary B, Hallas J, Schmidt JH, Ladebo L, Jensen PB, et al. Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA‐1273: A Danish Population‐Based Cohort Study. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.394
BibTeX
@article{Damkier2023,
author = {Damkier, Per and Cleary, Brian and Hallas, Jesper and Schmidt, Jesper H and Ladebo, Louise and Jensen, Peter B and Lund, Lars Christian},
title = {Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA‐1273: A Danish Population‐Based Cohort Study},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
doi = {10.1002/ohn.394}
}
EUVIMED